scholarly journals Extended anticoagulation treatment for cancer‐associated thrombosis ‐ rates of recurrence and bleeding beyond 6 months: A systematic review

2021 ◽  
Author(s):  
Florian Moik ◽  
Meaghan Colling ◽  
Isabelle Mahé ◽  
Luis Jara‐Palomares ◽  
Ingrid Pabinger ◽  
...  
Keyword(s):  
Systematic Review ◽  
Anticoagulation Treatment ◽  
Cancer Associated Thrombosis

scholarly journals Systematic Review and Meta‐analysis of Outcomes of Patients With Subsegmental Pulmonary Embolism With and Without Anticoagulation Treatment

2018 ◽  
Vol 25 (7) ◽  
pp. 828-835 ◽  
Author(s):  
Adam Bariteau ◽  
Lauren K. Stewart ◽  
Thomas W. Emmett ◽  
Jeffrey A. Kline
Keyword(s):  
Systematic Review ◽  
Pulmonary Embolism ◽  
Meta Analysis ◽  
Anticoagulation Treatment

scholarly journals Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review

2018 ◽  
Vol 164 ◽  
pp. S203-S204 ◽  
Author(s):  
B. Samuleson Bannow ◽  
A.Y.Y. Lee ◽  
A.A. Khorana ◽  
J.I. Zwicker ◽  
S. Noble ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Associated Thrombosis

Predictors of the Indefinite-Duration Anticoagulation Treatment Strategy In Patients with Cancer-Associated Thrombosis.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1097-1097
Author(s):  
David Spirk ◽  
Wolfgang Korte ◽  
Marc Husmann ◽  
Beat Frauchiger ◽  
Martin Banyai ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Metastatic Cancer ◽  
Anticoagulation Therapy ◽  
Medical Attention ◽  
Patients With Cancer ◽  
Anticoagulation Treatment ◽  
Recurrent Vte ◽  
Cancer Associated Thrombosis

Abstract Abstract 1097 Background: In patients with cancer and acute venous thromboembolism (VTE), current consensus guidelines recommend anticoagulation therapy for an indefinite duration or until the cancer is resolved. Methods and results: Among 1’247 patients with acute VTE enrolled in the Swiss Venous Thromboembolism Registry (SWIVTER) from 18 hospitals, 315 (25%) had cancer of whom 179 (57%) had metastatic disease, 159 (50%) ongoing or recent chemotherapy, and 83 (26%) tumor surgery within 6 months. Patients with cancer were older (66±14 vs. 60±19 years, p<0.001), more often hospitalized at the time of VTE diagnosis (46% vs. 36%, p=0.001), immobile for >3 days (25% vs. 16%, p<0.001), and more often had thrombocytopenia (6% vs. 1%, p<0.001) than patients without cancer. The 30-day rate of VTE-related death or recurrent VTE was 9% in cancer patients vs. 4% in patients without cancer (p<0.001), and the rates of bleeding requiring medical attention were 5% in both groups (p=0.57). Cancer patients received indefinite-duration anticoagulation treatment more often than patients without cancer (47% vs. 19%, p<0.001), and LMWH mono-therapy during the initial 3 months was prescribed to 45% vs. 8%, p<0.001, respectively. Among patients with cancer, prior VTE (OR 4.0, 95%CI 2.0–8.0), metastatic disease (OR 3.0, 95%CI 1.7–5.2), outpatient status at the time of VTE diagnosis (OR 3.8, 95%CI 1.9–7.6), and inpatient treatment (OR 4.4, 95%CI 2.1–9.2) were independently associated with the prescription of indefinite-duration anticoagulation treatment. Conclusions: Less than half of the cancer patients with acute VTE received a prescription for indefinite-duration anticoagulation treatment. Recurrent VTE, metastatic cancer, outpatient VTE diagnosis, and VTE requiring hospitalization were associated with an increased use of this strategy. Disclosures: Spirk: sanofi-aventis (suisse) sa: Employment.

scholarly journals The efficacy and safety of DOACs versus LMWH for cancer‐associated thrombosis: A systematic review and meta‐analysis

2020 ◽  
Vol 105 (3) ◽  
pp. 360-362 ◽  
Author(s):  
Derrick L. Tao ◽  
Sven R. Olson ◽  
Thomas G. DeLoughery ◽  
Joseph J. Shatzel
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Cancer Associated Thrombosis

Contralateral deep vein thrombosis after stenting across the iliocaval confluence in chronic venous disease – A systematic review

2019 ◽  
Vol 35 (4) ◽  
pp. 221-230 ◽  
Author(s):  
Luis Duarte-Gamas ◽  
João P Rocha-Neves ◽  
António Pereira-Neves ◽  
Marina Dias-Neto ◽  
Niels Baekgaard
Keyword(s):  
Systematic Review ◽  
Deep Vein Thrombosis ◽  
Iliac Vein ◽  
Venous Disease ◽  
Antithrombotic Treatment ◽  
Vein Thrombosis ◽  
Anticoagulation Treatment ◽  
Post Thrombotic Syndrome ◽  
Deep Vein

Objective Stenting of the iliac veins is increasingly considered in the presence of symptomatic obstructive chronic lesions in the iliac vein segment. However, it is often necessary to extend the stented zone into the inferior vena cava, increasing the risk of contralateral iliac vein thrombosis. This study aims to review the current literature concerning the incidence of contralateral deep vein thrombosis after stenting across the iliocaval confluence. Methods A systematic review from potentially relevant published articles reporting contralateral deep vein thrombosis after iliac venous stenting between January 2007 and February 2019 was performed. Results A total of 764 references were retrieved initially. Twelve studies reporting events of contralateral deep vein thrombosis were selected for review, with a total of 1864 patients. Contralateral deep vein thrombosis incidence varied between 0% and 15.6%. The post-interventional and follow-up anticoagulation regimens were heterogeneous between studies. The decision to maintain patients on anticoagulation and the duration of treatment was based on the presence of comorbidities, hypercoagulable states, post-thrombotic syndrome and history of recurrent deep vein thrombosis. Patients with non-thrombotic iliac vein lesions were either anticoagulated for three or six months after stenting or received no anticoagulation. Patients with post-thrombotic syndrome were anticoagulated for longer periods. Most studies (eight studies) used an oral vitamin K antagonist agent. The data on compliance with anticoagulation treatment is scarce and few references present data on whether contralateral deep vein thrombosis occurred during anticoagulation treatment. The use of antiplatelet agents in addition to the anticoagulant treatment in the follow-up period was also variable. Conclusion The incidence of contralateral deep vein thrombosis due to iliac vein jailing is not negligible and reported being as high as 15.6%. Large-scale studies on the ideal antithrombotic treatment and its impact are necessary. It is possible that patients with stent crossing the iliocaval confluence might benefit from long-term antithrombotic treatment.

Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis

2014 ◽  
Vol 134 (6) ◽  
pp. 1214-1219 ◽  
Author(s):  
Marc Carrier ◽  
Chris Cameron ◽  
Aurélien Delluc ◽  
Lana Castellucci ◽  
Alok A. Khorana ◽  
...  
Keyword(s):  
Systematic Review ◽  
Anticoagulant Therapy ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Cancer Associated Thrombosis
Sign in / Sign up

Export Citation Format

Share Document